Gamco Investors INC. ET AL Increases Stock Holdings in Vericel Co. (NASDAQ:VCEL)

Posted by on Jun 12th, 2023

Gamco Investors INC. ET AL lifted its stake in shares of Vericel Co. (NASDAQ:VCEL – Get Rating) by 53.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 17,185 shares of the biotechnology company’s stock after buying an additional 6,000 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Vericel were worth $453,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Advisors Asset Management Inc. increased its holdings in Vericel by 6.7% during the 3rd quarter. Advisors Asset Management Inc. now owns 7,197 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 452 shares during the last quarter. Arizona State Retirement System increased its holdings in Vericel by 4.0% during the 4th quarter. Arizona State Retirement System now owns 11,981 shares of the biotechnology company’s stock worth $316,000 after purchasing an additional 457 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in Vericel by 6.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 9,986 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 644 shares during the last quarter. Prudential Financial Inc. increased its holdings in Vericel by 1.5% during the 3rd quarter. Prudential Financial Inc. now owns 50,834 shares of the biotechnology company’s stock worth $1,208,000 after purchasing an additional 768 shares during the last quarter. Finally, Arcadia Investment Management Corp MI purchased a new stake in Vericel during the 4th quarter worth approximately $26,000.

Vericel Price Performance

NASDAQ:VCEL traded down $0.38 during midday trading on Monday, reaching $34.58. 115,665 shares of the company traded hands, compared to its average volume of 338,167. Vericel Co. has a twelve month low of $17.30 and a twelve month high of $35.78. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -93.35 and a beta of 1.77. The company has a fifty day moving average price of $32.09 and a 200 day moving average price of $29.02.

Vericel (NASDAQ:VCEL – Get Rating) last released its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). Vericel had a negative net margin of 10.11% and a negative return on equity of 9.26%. The company had revenue of $41.02 million for the quarter, compared to analyst estimates of $38.45 million. On average, equities research analysts forecast that Vericel Co. will post -0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Stephens lifted their price objective on Vericel from $39.00 to $42.00 in a report on Thursday, May 11th. Truist Financial lifted their target price on Vericel from $31.00 to $36.00 in a research report on Thursday, May 11th. Finally, StockNews.com initiated coverage on Vericel in a research report on Thursday, May 18th. They issued a “hold” rating for the company. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $37.25.

Vericel Company Profile

(Get Rating)

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee.

Read More

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.